World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation.

Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Birte Glenthøj, Wagner F Gattaz, Florence Thibaut, Hans-Jürgen Möller, A Carlo Altamura (Collaborator), Nancy Andreasen (Collaborator), Thomas R E Barnes (Collaborator), M Emin Ceylan (Collaborator), Jorge Ciprian Ollivier (Collaborator), Timothy Crow (Collaborator), Aysen Esen Danaci (Collaborator), Anthony David (Collaborator), Michael Davidson (Collaborator), Bill Deakin (Collaborator), Helio Elkis (Collaborator), Lars Farde (Collaborator), Wolfgang Gaebel (Collaborator)Bernd Gallhofer (Collaborator), Jes Gerlach (Collaborator), Steven Richard Hirsch (Collaborator), Carlos Roberto Hojaij (Collaborator), Michael Hwang (Collaborator), Hai Gwo Hwo (Collaborator), Assen Verniaminov Jablensky (Collaborator), Marek Jarema (Collaborator), John Kane (Collaborator), Takuja Kojima (Collaborator), Veronica Larach (Collaborator), Jeffrey Lieberman (Collaborator), Herbert Meltzer (Collaborator), Sergey Mosolov (Collaborator), Driss Moussaoui (Collaborator), Jean-Pierre Olié (Collaborator), Antonio Pacheco Palha (Collaborator), Asli Sarandöl (Collaborator), Mitsumoto Sato (Collaborator), Heinrich Sauer (Collaborator), Nina Schooler (Collaborator), Bilgen Taneli (Collaborator), Lars von Knorring (Collaborator), Daniel Weinberger (Collaborator), Shigeto Yamawaki (Collaborator)

    Research output: Contribution to journalArticlepeer-review

    Abstract

    These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.

    Keywords

    • comorbid depression
    • comorbid substance use disorder
    • pregnancy
    • schizophrenia
    • suicidality

    Fingerprint

    Dive into the research topics of 'World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation.'. Together they form a unique fingerprint.

    Cite this